ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. cut its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 23.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 60,420 shares of the biotechnology company’s stock after selling 18,185 shares during the period. ADMA Biologics accounts for approximately 2.0% of Mesirow Financial Investment Management Inc.’s portfolio, making the stock its 6th biggest holding. Mesirow Financial Investment Management Inc.’s holdings in ADMA Biologics were worth $399,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in ADMA Biologics by 182.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company’s stock worth $5,761,000 after purchasing an additional 1,039,893 shares during the period. HighTower Advisors LLC increased its holdings in shares of ADMA Biologics by 111.1% in the third quarter. HighTower Advisors LLC now owns 72,517 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 38,160 shares in the last quarter. Invesco Ltd. increased its holdings in shares of ADMA Biologics by 8.5% in the third quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company’s stock valued at $19,393,000 after buying an additional 426,446 shares in the last quarter. Algert Global LLC bought a new position in shares of ADMA Biologics in the third quarter valued at $80,000. Finally, Qube Research & Technologies Ltd increased its holdings in shares of ADMA Biologics by 22.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after buying an additional 224,696 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 1.7 %

Shares of ADMA Biologics stock traded down $0.19 during trading on Wednesday, hitting $11.21. 1,576,006 shares of the stock traded hands, compared to its average volume of 2,833,237. The company has a fifty day moving average price of $9.31 and a two-hundred day moving average price of $6.83. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $11.68. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm had revenue of $81.90 million during the quarter, compared to analyst estimates of $77.28 million. During the same period in the previous year, the company earned ($0.03) EPS. The company’s revenue for the quarter was up 43.9% on a year-over-year basis. As a group, research analysts forecast that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

Wall Street Analyst Weigh In

ADMA has been the topic of several research reports. Cantor Fitzgerald upped their price target on ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Mizuho boosted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Raymond James increased their target price on ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Finally, HC Wainwright upped their price target on ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $10.72, for a total value of $1,072,000.00. Following the transaction, the chief executive officer now directly owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.